FIG. 1




Median PFS 6.3 months vs 1 month*
HR=0.15, 95% CI (0.09, 0.25)
P<0.0001
Placebo (n=44)
Ripretinib (n=85)
Events, n (%) 37 (84.1%) 51 (60%)
Censored, n (%) 7 (15.9%) 34 (40%)
PFS 6 months, % (95% CI) 3.2% (0.2, 13.8) 51% (39.4, 61.4)
Survival Probability (%)
100
80
60
40
20
0
+ Censored
Ripretinib 160 mg QD
Placebo
0 2 4 6 8 10 12 14
Progression Free-Survival (Months)
Number of Patients at Risk:
Ripretinib 160 mg QD 85 64 52 37 18 8 3 0
Placebo 44 7 4 1 1 0
*Double-blind period

FIG. 2



*Due to hierarchal testing procedures of the end points, the OS end point could not be formally tested because the ORR was not statistically significant.

FIG. 3



Median OS (Months) 95% CI
Ripretinib 15.1 (12.3, 18.1)
Placebo Patients with Crossover ---------- 11.6 (8.3,)
Placebo Patients w/o Crossover ———— 1.8 (0.9, 4.9)
Survival Probability (%)
100
80
60
40
20
0
+ Censored
0
8
16
24
32
40
48
56
64
72
Overall Survival (Months)
Number of Patients at Risk
Ripretinib 85 81 76 70 57 38 16 5 2 0
Placebo Patients with Crossover 29 28 24 22 15 10 5 1 0 0
Placebo Patients w/o Crossover 15 6 5 2 2 0 0 0 0 0

FIG. 4




Lines of Therapy Median PFS 95% CI
2 46.4 (24.0 , 60.0)
3 36.3 (23.9 , 48.4)
≥4 23.9 (15.9 , 24.3)
Survival Probability
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0 14 28 42 56 70 84 98 112 126
PFS (Weeks)
Lines of Therapy: 2 3 ≥4
at Risk
2 n=31 25 18 15 11 7 3 0 0 0
3 n=28 22 15 12 6 4 3 2 0 0
>=4 n=83 52 28 17 14 9 6 2 0 0

FIG. 5



Treatment	Change from Baseline	Percentage of Patients
Ripretinib	Improvement and No Change	67
	Deterioration > MCID	33
Placebo	Improvement and No Change	41
	Deterioration > MCID	59

FIG. 6

6A
EORTC QLQ-C30 (version 3)
Physical Function Questions
6B
Physical Function Score Change from Baseline
These scores are converted to a scale ranging from 0 to 100. A larger value is better and a lower value is best.
ripretinib
placebo
ripretinib: 1.6
placebo: - 8.9
p-value: 0.004
Baseline
6 weeks
n=32
ripretinib 160mg BID
n = 71
6C
Treatment
Change from Baseline
Percentage of Patients
Ripretinib
Improvement and No Change
68
Deterioration > MCID
32
Placebo
Improvement and No Change
44
Deterioration > MCID
56

Role Function Questions

During the past week:	Not at All	A Little	Quite a Bit	Very Much
6. Were you limited in doing either your work or other daily activities?	1	2	3	4
7. Were you limited in pursuing your hobbies or other leisure time activities?	1	2	3	4

These scores are converted to a scale ranging from 0 to 100. A larger value is good and a lower value is bad

FIG. 7A





FIG. 7B

Treatment	Change from Baseline	Percentage of Patients
Ripretinib	Improvement and No Change	77
	Deterioration > MCID	23
Placebo	Improvement and No Change	50
	Deterioration > MCID	50

FIG. 7C

SUBSTITUTE SHEET (RULE 26)

FIG. 8




8B

Treatment	Change from Baseline	Percentage of Patients
Ripretinib	Improvement and No Change	74
	Deterioration > MCID	26
Placebo	Improvement and No Change	47
	Deterioration > MCID	53

FIG. 9

9A



9B

Treatment	Change from Baseline	Percentage of Patients
Ripretinib	Improvement and No Change	79
	Deterioration > MCID	21
Placebo	Improvement and No Change	59
	Deterioration > MCID	41

FIG. 10



VAS
Change from baseline (mean +/- SD)
20
10
0
-10
-20
Cycle 1, Day 15
Cycle 2, Day 1
Cycle 3, Day 1
Cycle 4, Day 1
Cycle 5, Day 1
Cycle 6, Day 1
Cycle 7, Day 1
Cycle 8, Day 1
Cycle 9, Day 1
Cycle 10, Day 1
Cycle 11, Day 1
Cycle 12, Day 1
Cycle 13, Day 1
Cycle 14, Day 1
Cycle 15, Day 1

FIG. 11





FIG. 12

12A



12B




FIG. 13

	Placebo (N=44)	Placebo /Ripretinib (N=29)	Ripretinib (N=85)
Events n (%)	37 (84.1)	13 (44.8)	51 (60.0)
Censored n (%)	7 (15.9)	**16 (55.1)**	34 (40.0)
Median PFS (weeks) % (95% CI)	4.1 (4.0, 7.3)	20.0 (8.0, NE)	27.6 (20.0, 29.9)

*NE = Not Estimable





FIG. 14


14A
Kaplan-Meier Plot of Progression-Free Survival Based on BICR in Double-Blind Treatment Period for patients randomized to 150 mg QD then escalated to 150 mg BID
14B
Kaplan-Meier Plot of Progression-Free Survival based on BICR in Open-Label Treatment Period for patients randomized to 150 mg QD then escalated to 150 mg BID
14C
Events n (%) 17 (54.8)
Censored n (%) 14 (45.2)
Median PFS (weeks) & (95% CI) 13.6 (7.7, 18.1)

Gene	Subj ID	Arm	PFS (Weeks)	Censored?	Mutation
Wild Type	1	DCC-2618 150 mg QD	11.1429	Yes	None
Wild Type	2	DCC-2618 150 mg QD	52.1429	Yes	SDHC/TP53
Wild Type	3	DCC-2618 150 mg QD	24.7143	Yes	None
Wild Type	4	DCC-2618 150 mg QD	8.7143	No	SDHC/ATRX
Wild Type	5	DCC-2618 150 mg QD	36.4286	Yes	KRAS
Wild Type	6	DCC-2618 150 mg QD	8.7143	No	MCL1 Amplification
Wild Type	7	DCC-2618 150 mg QD	26	No	NF1
Wild Type	8	Placebo	4	No	CDKN2A/CDKN28/PTEN I
Wild Type	9	Placebo	36	Yes	SDHA/TP53
Wild Type	10	Placebo	9	No	NF1

FIG. 15

FIG. 16



16A
16B
Product-Limit Survival Estimates
Exon 11 R
Non-Exon 11 R
Non-Exon 11 P
Exon 11 P
Progression-free survival (weeks)
Overall survival (weeks)

FIG. 17



17A
Product-Limit Survival Estimates
PFS
Exon 11 R
Exon 11 P
Exon 9 R
Progression-free survival (weeks)
17B
Product-Limit Survival Estimates
OS
Exon 11 R
Exon 11 P
Exon 9 R
Overall survival (weeks)

FIG. 18




18A
PFS
Product-Limit Survival Estimates
Censored
WT-R
Exon 11 R
NAA R
Exon 9 R
Survival Probability
Progression-free survival (weeks)
18B
OS
Overall survival (weeks)

FIG. 19



Gene	Subj ID	Arm	PFS (Weeks)	Censored?
KIT Other Exons	11	DCC-2618 150 mg QD	3.0	Yes
KIT Other Exons	12	DCC-2618 150 mg QD	12.9	No
KIT Other Exons	13	Placebo	3.9	No
KIT Other Exons	14	Placebo	7.3	No
PDGFRA	15	DCC-2618 150 mg QD	4.1	No
PDGFRA	16	DCC-2618 150 mg QD	7.6	No
PDGFRA	17	DCC-2618 150 mg QD	28.1	Yes

FIG. 20

FIG. 21



First Appearance
Worst Grade
1.9
2.1
First Appearance
Worst Grade
1.9
1.9
Alopecia
(n = 44)
PPES
(n = 18)
0
0.5
1
1.5
2
Time (months)

FIG. 22A



Physical function in patients receiving ripretinib with and without alopecia
With alopecia
Without alopecia
Cycle 1, Day 15
Cycle 2, Day 1
Cycle 3, Day 1
Cycle 4, Day 1
Cycle 5, Day 1
Cycle 6, Day 1
Cycle 7, Day 1
Cycle 8, Day 1
Cycle 9, Day 1
Cycle 10, Day 1
Visit

FIG. 22B



Role function in patients receiving ripretinib with and without alopecia
With alopecia
Without alopecia
Cycle 1, Day 15
Cycle 2, Day 1
Cycle 3, Day 1
Cycle 4, Day 1
Cycle 5, Day 1
Cycle 6, Day 1
Cycle 7, Day 1
Cycle 8, Day 1
Cycle 9, Day 1
Cycle 10, Day 1
Visit

FIG. 22C



Physical function in patients receiving ripretinib with and without PPES
Without PPES
With PPES
Cycle 1, Day 15
Cycle 2, Day 1
Cycle 3, Day 1
Cycle 4, Day 1
Cycle 5, Day 1
Cycle 6, Day 1
Cycle 7, Day 1
Cycle 8, Day 1
Cycle 9, Day 1
Cycle 10, Day 1
Visit

FIG. 22D



Role function in patients receiving ripretinib with and without PPES
With PPES
Without PPES
Cycle 1, Day 15
Cycle 2, Day 1
Cycle 3, Day 1
Cycle 4, Day 1
Cycle 5, Day 1
Cycle 6, Day 1
Cycle 7, Day 1
Cycle 8, Day 1
Cycle 9, Day 1
Cycle 10, Day 1
Visit

FIG. 23A



Overall health in patients receiving ripretinib with and without alopecia
With alopecia
Without alopecia
EORTC QLQ change from baseline (mean +/- SD)
4
3
2
1
0
-1
-2
-3
-4
Cycle 1, Day 15
Cycle 2, Day 1
Cycle 3, Day 1
Cycle 4, Day 1
Cycle 5, Day 1
Cycle 6, Day 1
Cycle 7, Day 1
Cycle 8, Day 1
Cycle 9, Day 1
Cycle 10, Day 1
Visit

FIG. 23B



Overall quality of life in patients receiving ripretinib with and without alopecia
With alopecia
Without alopecia
EORTC30 change from baseline (mean +/- SD)
4
3
2
1
0
-1
-2
-3
-4
Cycle 1, Day 15
Cycle 2, Day 1
Cycle 3, Day 1
Cycle 4, Day 1
Cycle 5, Day 1
Cycle 6, Day 1
Cycle 7, Day 1
Cycle 8, Day 1
Cycle 9, Day 1
Cycle 10, Day 1
Visit

FIG. 23C



Overall health in patients receiving ripretinib with and without PPES
Without PPES
With PPES
EORTC's change from baseline (mean +/- SD)
4
3
2
1
0
-1
-2
-3
-4
Cycle 1, Day 15
Cycle 2, Day 1
Cycle 3, Day 1
Cycle 4, Day 1
Cycle 5, Day 1
Cycle 6, Day 1
Cycle 7, Day 1
Cycle 8, Day 1
Cycle 9, Day 1
Cycle 10, Day 1
Visit

FIG. 23D



Overall quality of life in patients receiving ripretinib with and without PPES
With PPES
Without PPES
EORTC 30 change from baseline (mean +/- SD)
Cycle 1, Day 15
Cycle 2, Day 1
Cycle 3, Day 1
Cycle 4, Day 1
Cycle 5, Day 1
Cycle 6, Day 1
Cycle 7, Day 1
Cycle 8, Day 1
Cycle 9, Day 1
Cycle 10, Day 1
Visit

FIG. 24A



State of health (VAS) in patients receiving ripretinib with and without alopecia
With alopecia
Without alopecia
Cycle 1, Day 15
Cycle 2, Day 1
Cycle 3, Day 1
Cycle 4, Day 1
Cycle 5, Day 1
Cycle 6, Day 1
Cycle 7, Day 1
Cycle 8, Day 1
Cycle 9, Day 1
Cycle 10, Day 1
Visit

FIG. 24B



State of health (VAS) in patients receiving ripretinib with and without PPES
Without PPES
With PPES
EQ5D3L Change from baseline (mean +/- SD)
70
60
50
40
30
20
10
0
-10
-20
-30
-40
-50
-60
-70
Cycle 1, Day 15
Cycle 2, Day 1
Cycle 3, Day 1
Cycle 4, Day 1
Cycle 5, Day 1
Cycle 6, Day 1
Cycle 7, Day 1
Cycle 8, Day 1
Cycle 9, Day 1
Cycle 10, Day 1
Visit

FIG. 25A

PFS1



Median PFS(Months) 95% CI
2nd Line: 8.3 (3.5, 13.8)
3rd Line: 8.3 (1.8, 11.1)
>=4th Line: 5.5 (1.9, 8.1)
+ Censored
Survival Probability (%)
100
80
60
40
20
0
0
4
8
12
16
20
24
28
Progression Free Survival (Months)
2nd Line
3rd Line
>=4th Line
Number of Patients at Risk:
2nd Line 8 6 4 2 1 1 0 0
3rd Line 17 13 9 4 2 1 1 0
>=4th Line 39 20 14 5 3 0

FIG. 25B

PFS2



Median PFS(Months) 95% CI
2nd Line: 5.6 (1.4, -)
3rd Line: 3.7 (2.4, 7.4)
>=4th Line: 3.7 (2.7, 6.9)
Survival Probability (%)
100
80
60
40
20
0
+ Censored
0
4
8
12
16
20
24
Progression Free Survival (Months)
2nd Line
3rd Line
>=4th Line
Number of Patients at Risk:
2nd Line 8 4 1 0 1 0 0
3rd Line 17 7 2 1 2 1 0
>=4th Line 39 18 12 3

FIG. 26




KIT exon 9
Ripretinib
Placebo
KIT exon 11
Ripretinib
Placebo
KIT exon 13
Ripre
Placebo
KIT exon 17
Ripretinib
Placebo
26A
26B
26C
26D

FIG. 27


Strata
Exon 9
Exon 11
Exon 13
Exon 17
probability of survival
1.00
0.75
0.50
0.25
0.00
0
25
50
75
100
PFS (weeks)
Number at risk
7
27
9
3
13
5
1
4
2
0
0
1
0
0
1
0
0
25
50
75
100
PFS (weeks)